Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: KLH who wrote (2498)	2/3/1999 10:48:00 PM
From: BWAC	Read Replies (1) \| Respond to of 2553

I think one of the biggest problems here with GENZL can be traced directly to the internut mania and craze. Speculative stocks trading at historic low valuations simply have not recovered from the crash/correction/whatever from last September and October. Tax loss selling conspired to take these type stocks even lower. All the speculative money is off chasing the .coms of the world. It doesn't have time or the attention span to consider companies like GENZL. Until this changes small boitechs will suffer more than likely. And it will change. Oneday. Someday. Eventually?? I suspect the true value of GENZL would normally be about 8 to 10. But given the above scenario 5 or 6 would be close to full valuation. Under no "rational" circumstances should a well backed and funded Biotech stock with 2 approved products on the market, generating sales be relegated to the $3 and under scene. I can't or rather I won't chase vapor.com, so here I plan to sit and mark time until the winds change. I feel like the exact same post could be applied to the GZMO tracking stock. Name one, just one cancer research stock which trades this low. Even CLPA with an apparently failed phase 3 trial is $8. Go figure. Or should I say go.com And if you want some other examples while I seem to be on a good vent: Compare LSI earned .00 and goes up to 26 from 20. VLSI earns .02 and falls from 13 to 11 which just happens to be below book value and darn near close to the $8 per share of CASH on hand. Or TUTS with 1.5 M in sales and a 850 M market cap. as compared to PAIR with 280 M in sales, earnings, and 750 M market cap.